Amova Asset Management Americas Inc. Decreases Stock Position in CareDx, Inc. $CDNA

Amova Asset Management Americas Inc. reduced its position in CareDx, Inc. (NASDAQ:CDNA) by 16.9% in the fourth quarter, HoldingsChannel.com reports. The institutional investor owned 1,446,616 shares of the company’s stock after selling 293,448 shares during the period. Amova Asset Management Americas Inc.’s holdings in CareDx were worth $27,254,000 as of its most recent filing with the Securities and Exchange Commission (SEC).

A number of other large investors have also bought and sold shares of the company. Cerity Partners LLC purchased a new stake in CareDx in the fourth quarter worth $229,000. Franklin Resources Inc. increased its position in CareDx by 3.8% in the fourth quarter. Franklin Resources Inc. now owns 103,703 shares of the company’s stock worth $1,954,000 after buying an additional 3,774 shares during the last quarter. WINTON GROUP Ltd purchased a new stake in CareDx in the fourth quarter worth $229,000. Globeflex Capital L P lifted its stake in shares of CareDx by 12.4% during the 4th quarter. Globeflex Capital L P now owns 79,795 shares of the company’s stock valued at $1,503,000 after buying an additional 8,792 shares in the last quarter. Finally, State of Wyoming purchased a new stake in shares of CareDx during the 4th quarter valued at approximately $155,000.

Analyst Ratings Changes

A number of analysts recently commented on CDNA shares. Wells Fargo & Company upped their price target on shares of CareDx from $18.00 to $21.00 and gave the company an “equal weight” rating in a research note on Wednesday, February 25th. BTIG Research upped their price target on shares of CareDx from $26.00 to $28.00 and gave the company a “buy” rating in a research note on Wednesday, April 29th. Weiss Ratings restated a “sell (d)” rating on shares of CareDx in a research note on Wednesday, May 27th. Finally, Wall Street Zen upgraded shares of CareDx from a “buy” rating to a “strong-buy” rating in a research note on Sunday, May 3rd. One analyst has rated the stock with a Buy rating, four have given a Hold rating and one has issued a Sell rating to the company. Based on data from MarketBeat, CareDx presently has an average rating of “Hold” and an average price target of $25.00.

CareDx Price Performance

NASDAQ CDNA opened at $22.75 on Wednesday. The company’s 50 day simple moving average is $20.44 and its two-hundred day simple moving average is $19.48. CareDx, Inc. has a 1 year low of $10.96 and a 1 year high of $24.02. The stock has a market capitalization of $1.18 billion, a PE ratio of -142.19 and a beta of 2.49.

CareDx (NASDAQ:CDNA) last announced its quarterly earnings results on Tuesday, April 28th. The company reported $0.34 EPS for the quarter, beating the consensus estimate of $0.11 by $0.23. CareDx had a negative net margin of 2.01% and a negative return on equity of 2.65%. The firm had revenue of $117.70 million during the quarter, compared to the consensus estimate of $102.03 million. During the same period last year, the firm earned $0.09 EPS. The business’s quarterly revenue was up 39.3% compared to the same quarter last year. On average, research analysts anticipate that CareDx, Inc. will post 0.22 EPS for the current year.

Insider Activity at CareDx

In other news, CEO John Walter Hanna, Jr. sold 10,282 shares of CareDx stock in a transaction dated Thursday, April 16th. The shares were sold at an average price of $21.12, for a total transaction of $217,155.84. Following the sale, the chief executive officer owned 676,475 shares of the company’s stock, valued at approximately $14,287,152. The trade was a 1.50% decrease in their position. The sale was disclosed in a document filed with the SEC, which is accessible through this hyperlink. The transaction was executed under a pre-arranged Rule 10b5-1 trading plan. Corporate insiders own 2.40% of the company’s stock.

CareDx Company Profile

CareDx, Inc (NASDAQ: CDNA) is a precision diagnostics company focused on the care of transplant patients. The firm develops and commercializes non‐invasive tests designed to detect organ transplant rejection and infection risk, helping physicians make informed management decisions throughout the post‐transplant journey.

The company’s core product portfolio includes AlloMap®, a gene expression profiling test for heart transplant recipients, and AlloSure®, a donor‐derived cell‐free DNA assay used primarily in kidney transplant monitoring.